Part of the answer is this:

" Proof of concept in the proposed 10 patient aplastic anemia trial will allow us to expand into the larger market of blood production disorders which exceeds $4.84 billion per year and currently addressed by growth factors such as Neupogen(R), Neulasta(R), Leukine(R) and Revolade(R). ( www.wikinvest.com/stock/Amgen )."

Aplastic anemia is the first of four indications outlined for the Hema program. Not able to pull those just now, but they were outlined in a news release. Many drug programs begin with an orphan indication for proof of concept and safety study.